Alterity Therapeutics Files 6-K, Includes Phase 2 Presentation
Ticker: PRNAF · Form: 6-K · Filed: Apr 28, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, presentation, clinical-trial
TL;DR
Alterity Therapeutics filed a 6-K with a Phase 2 presentation from the MSA Symposium 2025.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on April 28, 2025, to report its activities for April 2025. This filing incorporates by reference into several of their existing Registration Statements on Form S-8 and Form F-3. The report includes Exhibit 99.1, which is a presentation from the Alterity Phase 2 at the MSA Symposium 2025.
Why It Matters
This filing provides an update on Alterity Therapeutics' activities and incorporates a presentation on their Phase 2 trial, which could be material for investors tracking their drug development progress.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily incorporates existing documents and does not appear to contain new material financial or strategic information.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- MSA Symposium 2025 (event) — Presentation topic
- Form S-8 (document) — Incorporated by reference
- Form F-3 (document) — Incorporated by reference
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K is to report activities for the month of April 2025 and to incorporate by reference Exhibit 99.1, which is a presentation from the Alterity Phase 2 at the MSA Symposium 2025, into existing registration statements.
Which registration statements is this 6-K filing being incorporated into?
This Form 6-K is being incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is the specific exhibit included with this filing?
The specific exhibit included with this filing is Exhibit 99.1, titled 'Alterity Phase 2 Presentation at MSA Symposium 2025'.
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office address of Alterity Therapeutics Limited is Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Alterity Therapeutics indicates that it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 28, 2025 regarding ALTERITY THERAPEUTICS LTD (PRNAF).